Jason Butler
Stock Analyst at JMP Securities
(2.32)
# 2,554
Out of 4,884 analysts
145
Total ratings
38.19%
Success rate
-0.26%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $20.95 | +76.61% | 14 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $14.92 | +161.48% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $1.62 | +270.37% | 11 | Jun 12, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $78 → $29 | $6.44 | +350.66% | 10 | May 27, 2025 | |
| VIGL Vigil Neuroscience | Downgrades: Market Perform | n/a | $7.99 | - | 5 | May 22, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $74.41 | +34.39% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $15.67 | +142.50% | 8 | May 7, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $7.96 | +314.57% | 3 | Apr 30, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $34.66 | +125.04% | 16 | Apr 10, 2025 | |
| RAPP Rapport Therapeutics | Initiates: Market Outperform | $28 | $12.04 | +132.56% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $9.74 | +84.80% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.17 | +241.88% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $543.48 | +28.98% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $10.27 | +221.32% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $4.82 | +86.72% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $54.00 | +35.19% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.72 | +141.94% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.34 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $50 → $23 | $1.23 | +1,769.92% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $11.62 | +63.51% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $0.77 | +2,772.06% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.65 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $8.80 | +477,172.73% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $7.89 | +1,370.22% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.24 | +177.78% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.34 | - | 1 | Dec 2, 2020 |
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $20.95
Upside: +76.61%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $14.92
Upside: +161.48%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.62
Upside: +270.37%
Prothena Corporation
May 27, 2025
Maintains: Market Outperform
Price Target: $78 → $29
Current: $6.44
Upside: +350.66%
Vigil Neuroscience
May 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $7.99
Upside: -
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $74.41
Upside: +34.39%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $15.67
Upside: +142.50%
ABIVAX Société Anonyme
Apr 30, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $7.96
Upside: +314.57%
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $34.66
Upside: +125.04%
Rapport Therapeutics
Apr 8, 2025
Initiates: Market Outperform
Price Target: $28
Current: $12.04
Upside: +132.56%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $9.74
Upside: +84.80%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.17
Upside: +241.88%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $543.48
Upside: +28.98%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $10.27
Upside: +221.32%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $4.82
Upside: +86.72%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $54.00
Upside: +35.19%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.72
Upside: +141.94%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.34
Upside: -
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $1.23
Upside: +1,769.92%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $11.62
Upside: +63.51%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $0.77
Upside: +2,772.06%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.65
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $8.80
Upside: +477,172.73%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $7.89
Upside: +1,370.22%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.24
Upside: +177.78%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.34
Upside: -